We propose circulating Gal-9 as a candidate biomarker of anti-PD-1 resistance and support the rationale for combined blockade of PD-1 and Tim-3 to enhance immunotherapeutic efficacy in GC. The gene discussed is RPL17; the disease is gastric cancer.